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To the Editor: The position statement of the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) recently published an updated algorithm for the initiation and 
adjustment of therapy for the management of hyperglycaemia in type 2 diabetes [1]. Interestingly, from a clinical 
point of view, the paper recommends a patient-centred strategy and gives some key properties for each 
medication to help physicians choose the best option for an individual patient. This personalised approach should 
take into account the efficacy and safety profile of the glucose-lowering compound, its cost and some clinical 
characteristics of the diabetic patient. In contrast to the previous version [2] and taking into account previous 
criticism [3], dipeptidyl peptidase IV (DPP-4) inhibitors (also called gliptins) [4] are now considered a possible 
valuable alternative to other pharmacological options after failure to respond to metformin monotherapy. 
Considering the comparative efficacy of the various glucose-lowering agents combined with metformin, the 
remarkable Fig. 2 of the position statement, summarising general recommendations, indicates that the reduction 
in HbA1c is 'high' with sulfonylureas and with thiazolidinediones, whereas it is considered as 'intermediate' with 
DPP-4 inhibitors [1]. This discrimination is difficult to understand and does not reflect the currently available 
data. Moreover, it is partially in contradiction with the text of the position statement paper itself, which is much 
more nuanced: 
'The glucose-lowering effectiveness of non-insulin pharmacological agents is said to be high for 
metformin, sulfonylureas, TZDs and GLP-1 agonists ... and generally lower for ... DPP-4 inhibitors ... 
However, older drugs have typically been tested in clinical trial participants with higher baseline HbA1c, 
which is itself associated with greater treatment emergent glycaemic reductions, irrespective of therapy 
type. In head-to-head studies, any differential effects on glucose control are small.' 
Furthermore, in the chapter with the subtitle 'Advancing to dual combination therapy', the position statement 
continues as follows: 'On average, any second agent is typically associated with an approximate further reduction 
in HbA1c of ~1%', and concludes 'With a distinct paucity of long-term comparative-effectiveness trials available, 
uniform recommendations on the best agent to be combined with metformin cannot be made.' I agree that the 
text objectively reflects available data from the literature, but regret that Fig. 2, which provides a synthetic 
summary, does not! As in the previous consensus statement [2], the discrimination between the efficacy of oral 
glucose-lowering agents seems to rely more on opinion than on evidence [3]. I fear, however, that most 
physicians will just refer to the concise figure and, even if they read the more balanced information written in the 
core of the manuscript, they may not recall it later. 
As add-on therapy to metformin, all available data from the literature indicate that the efficacy of DPP-4 
inhibitors is similar to that of either sulfonylureas or thiazolidinediones [5-7]. This conclusion is supported not 
only by indirect comparisons [5, 6], but also by head-to-head trials comparing a DPP-4 inhibitor (for instance 
sitagliptin, vildagliptin or saxagliptin) and a sulfonylurea or a thiazolidinedione in patients not well controlled 
with metformin alone [7]. Several meta-analyses have confirmed the similar reduction in HbA1c with a DPP-4 
inhibitor and with a sulfonylurea or a thiazolidinedione in these conditions [5, 6]. For instance, in patients 
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specifically treated with metformin, an overall HbA1c reduction of -0.78% (95% CI -0.93, -0.64) was reported 
with DPP-4 inhibitors, which was not different from the -0.79% (-0.97, -0.62) with sulfonylureas and the -0.85% 
(-1.08, -0.66) with thiazolidinediones [5]. Head-to-head trials in metformin-treated patients confirmed a similar 
efficacy in reducing HbA1c between DPP-4 inhibitors and sulfonylureas (uptitrated glipizide or glimepiride; eight 
trials; change -0.56% vs -0.61%; NS) or between DPP-4 inhibitors and thiazolidinediones (rosiglitazone or 
pioglitazone; five trials; change -0.76% vs -0.83%; NS) [7]. 
Perhaps the inappropriate statement that DPP-4 inhibitors are less effective at reducing HbA1c levels comes from 
indirect comparisons, with early trials having tested the efficacy of glitazones (and sulfonylureas) in patients 
with poorly controlled diabetes (the higher the baseline HbA1c, the greater the reduction achieved irrespective of 
the pharmacological agent prescribed) [8]. Although this possibility is mentioned in the text by Inzucchi and 
colleagues, it is forgotten in the general recommendations provided in Fig. 2 [1]. Furthermore, concerning 
sulfonylureas, while the initial HbA1c reduction may be impressive, this favourable response is commonly 
followed by a progressive deterioration of glucose control (as recognised and briefly mentioned in the text of the 
position statement). 
It therefore does not seem justified, based on the available evidence, to state that the reduction in HbA1c is 
'intermediate' with DPP-4 inhibitors whereas it is qualified as 'high' with sulfonylureas or thiazolidinediones. 
Such a strong distinction in the general recommendations (the key figure of the position statement) may 
influence the prescription of physicians because a reduction in HbA1c is generally considered the most important 
surrogate endpoint in the management of type 2 diabetes. This distinction between DPP-4 inhibitors on the one 
hand and sulfonylureas and thiazolidinediones on the other can only be justified if the authors adjust the 
reduction in HbA1c according to the cost of the agent used. This is not the case because cost is considered as a 
separate item in the box summarising the overall evaluation for each pharmacological compound as provided in 
the otherwise nice algorithm of this position statement [1]. 
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